Data from ITN Lupus Nephritis Study to be presented at Upcoming Rheumatology and Nephrology Conferences
Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences. The ACCESS study examined whether the combination of abatacept (CTLA4-Ig) and cyclophosphamide is able to better induce tolerance compared to the Euro-Lupus regimen (low-dose pulse cyclophosphamide).